Gohil, Satyen H.
Iorgulescu, J. Bryan http://orcid.org/0000-0003-1405-3667
Braun, David A. http://orcid.org/0000-0003-4543-5553
Keskin, Derin B.
Livak, Kenneth J. http://orcid.org/0000-0001-9105-5856
Article History
Accepted: 30 October 2020
First Online: 4 December 2020
Competing interests
: D.A.B. has received non-financial support from Bristol Myers Squibb, honoraria from LM Education/Exchange Services and personal fees from Adept Field Solutions, Blueprint Partnerships, Charles River Associates, Dedham Group, Defined Health, Insight Strategy, Octane Global, Slingshot Insights and Trinity Group. D.B.K. has acted as an advisor of and has received consulting fees from Neon Therapeutics and owns equity in Aduro Biotech, Agenus, Armata Pharmaceuticals, Breakbio, BioMarin Pharmaceutical, Bristol Myers Squibb, Celldex Therapeutics, Editas Medicine, Exelixis, Gilead Sciences, IMV, Lexicon Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and Stemline Therapeutics. The other authors declare no competing interests.